Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Consume Fat Quick: 10 Demonstrated Activities for Ideal Outcomes - 2NASA loses contact with its Maven spacecraft orbiting Mars for the past decade
- 3Rick Steves Doesn't Want You Overlooking This Food Spot While In France
- 4I’m a neuroscientist who taught rats to drive − their joy suggests how anticipating fun can enrich human life
- 5Aspect Biosystems receives funding for cellular medicine project
- Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders
- This Flashy Old-School Design Trend From Italy Still Has A Place In Modern Kitchens
- Vote in favor of the bloom plan that adds a bit of excellence to your life!
- Expert advice for new stargazers: How to begin your amateur astronomy journey
- NAFFIC and Aware to Launch First China-Europe Digital Product Passport
- NASA astronauts take new moonsuit for a swim | Space photo of the day for Nov. 28, 2025
- McDonald's is bringing two 'KPop Demon Hunters' meals to McDonald's. Here's what they include and when they launch.
- 5 Language Learning Applications
